Bi-layer nanobubbles and method for their synthesis for targeted drug delivery

Bi-layer nanobubbles address the limitations of traditional nanobubbles by enhancing stability, drug loading, and tissue penetration, enabling precise and controlled delivery of multiple drugs using focused ultrasound, overcoming challenges in traditional nanobubble systems.

WO2024246800A1PCT designated stage expired Publication Date: 2024-12-05NASROLLAHI BOROUJENI FATEMEH +3
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
PCT/IB2024/055258
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-30
Filing Date
2024-05-30
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Traditional single-layer nanobubbles face limitations in stability, controlled drug release, limited drug loading capacity, and suboptimal tissue penetration, struggling to effectively deliver both hydrophobic and hydrophilic drugs simultaneously while maintaining drug stability and precision in targeted drug delivery.

Method used

The development of bi-layer nanobubbles with a thin lipid film hydration method, incorporating hydrophobic and hydrophilic drugs in separate layers, and optionally modifying the surface to include Exosome-derived drugs, enhances stability, drug loading capacity, and tissue penetration, allowing for controlled release and precise delivery using focused ultrasound.

Benefits of technology

Bi-layer nanobubbles improve stability, extend drug half-life, enable controlled release, increase drug loading capacity, and enhance tissue penetration, ensuring effective and precise delivery of therapeutic agents to target tissues while minimizing systemic side effects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IB2024055258_05122024_PF_FP_ABST
    Figure IB2024055258_05122024_PF_FP_ABST
Patent Text Reader

Abstract

This patent introduces a method for producing bilayer nanobubbles incorporating drugs. The process involves preparing a thin lipid film, incorporating hydrophobic and hydrophilic drugs, hydrating the film to form a suspension, and reducing particle size to nano dimensions. Further steps include placing the suspension in a neutral gas and applying sonication to form bilayer nanobubbles. Additionally, a third drug, such as Exosome-derived drug, can be incorporated onto the nanobubble surface through modification and subjected to freeze-thaw conditions. The modification process entails mixing components in a buffer, incubating, centrifuging, dissolving, and sonicating to achieve a modified surface.
Need to check novelty before this filing date? Find Prior Art

Description

Bi-Layer Nanobubbles and Method for Their Synthesis for Targeted Drug Delivery, Using Focused UltrasoundCROSS REFERRENCE TO RELATED DISCLOSURE

[0001] This disclosure claims the benefit of priority from Iranian Patent Application No. 140250140003001549, filed on May, 30, 2023, and entitled “The process of producing nanobubbles based on stable gas and drug loading in it for targeted drug delivery with focused ultrasound waves” which is incorporated by reference herein in its entirety.TECHNICAL FIELD

[0002] The present disclosure generally relates to targeted drug delivery and more specifically relates to a development of bilayer nanobubbles incorporating drugs for targeted drug delivery using focused ultrasound waves. And more specifically relates to development of bilayer nanobubbles incorporating Exosome-Derived drugs for targeted drug delivery using focused ultrasound waves.Background Art

[0003] This section introduces aspects that may help facilitate a better understanding of the disclosure. Accordingly, these statements are to be read in this light and are not to be understood as admissions about what is or is not prior art.

[0004] The utilization of advanced pharmaceutical systems, such as nanoliposomes and various nanoparticles, is crucial for delivering drugs to specific tissue areas, particularly in the treatment of disease.

[0005] Nanoliposomes are widely recognized as effective nanocarriers due to their high biocompatibility, low immunogenicity, and capacity to protect encapsulated drugs. However, achieving controlled and sustained drug release from liposomes remains a significant challenge.

[0006] To address these challenges, researchers have explored a variety of nanocarriers, including lipid nanoparticles, polymer nanoparticles, inorganic nanoparticles, solid lipid nanoparticles, and dendrimers While these approaches offerseveral benefits, they can also pose issues such as invasive, non-targeted delivery, and potentially alteration of drug properties.

[0007] One of the major hurdles in drug delivery is ensuring that the drug or the therapeutic agent effectively reaches the intended tissue without premature degradation or metabolism. Nanobubbles have emerged as a promising solution for targeted drug delivery system due to their responsiveness to ultrasound, which enhances drug delivery precision and efficiency.

[0008] Focused ultrasound waves when combined with nanobubbles, have demonstrated improved drug delivery efficiency. Nanobubbles compared to microbubbles, offer several advantages: they can penetrate deeper into tissue and cells, scatter focused ultrasound waves more effectively, and have a higher surface- to-volume ration, which enhances drug loading capabilities. Moreover, the use of focused ultrasound waves with nanobubbles provides strong spatial control over drug release, ensuring the therapeutic effect in confined to the target site and minimizing impact on healthy tissues.

[0009] Despite all these advantages, nanobubbles still have limitations in targeted drug delivery. Traditional nanobubbles may have challenges related to their stability, controlling drug release, their limited drug loading capacity, and suboptimal tissue penetration.

[0010] Existing technologies, such as those described in Patent No. US 2018 / 0252702 A1 and No. IN2919 / MUM / 2013, focus on single-layer nanobubbles, which restrict drug loading to the surface, thereby limiting the overall drug payload. Summary of Invention

[0011] The following provides a simplified summary of various aspects of the present disclosure to offer a basic understanding of such aspects. This summary is not an extensive overview of the disclosure and is not intended to identify key or critical elements of the disclosure, nor delineate any scope of the particular embodiments of the disclosure or any scope of the claims. Its sole purpose is to present some concepts of the disclosure in a simplified form as a prelude to the more detailed description that follows.

[0012] The present invention discloses a novel method for synthesizing bi-layer nanobubbles incorporating drugs, as well as the bi-layer nanobubbles themselves. In some exemplary embodiments, the process of producing bi-layer nanobubbles incorporating drugs may involve, in the initial step, preparing a thin lipid film by dissolving phospholipids in an organic solvent using the thin film hydration method. Phospholipids, such as dipalmitoyl phosphatidylcholine (DPPC) and phosphatidylethanolamine (PE), may be dissolved in a solvent to prepare the thin lipid film. At this stage, a first drug, which may be hydrophobic, can be incorporated.

[0013] In a subsequent step, the prepared thin lipid film may be hydrated with phosphate-buffered saline (PBS) at a specific temperature to form a suspension. During this hydration stage, a second drug, which may be hydrophilic, can be incorporated. The particle size of the resulting suspension may then be reduced to the nanoscale using an extruder. Nanobubbles can be formed by exposing the suspension to a neutral gas and applying sonication at the lipid phase transition temperature.

[0014] In another aspect, the invention discloses a method for synthesizing bi-layer nanobubbles that incorporate not only the first and second drugs but also a third drug, such as an Exosome-derived drugs as a biogenetic drug. This method may involve additional steps, including modifying the surface of the nanobubble to apply the Exosome-derived drugs and subjecting the nanobubble to freeze-thaw conditions after adding the Exosome-derived drug.

[0015] The surface modification of the nanobubble may involve forming a first mixture by combining EDC (1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide), NHS (N- hydroxysuccinimide), and Apo-Transferrin in a PBS buffer; forming a second mixture that may be formed by adding the nanobubble-incorporated drug to the first mixture. The second mixture may be incubated and centrifuged to form a precipitate, which can then be dissolved in PBS to obtain a homogeneous solution. This solution may be sonicated in a bath sonicator to form a modified surface on the nanobubble containing the first and the second drug. The Exosome-derived drug can then be incorporated onto this modified surface, and the nanobubble may be subjected to freeze-thaw conditions to finalize the incorporation of the first, second, and third drugs.

[0016] This invention provides a comprehensive solution for synthesizing bi-layer nanobubbles with enhanced drug delivery capabilities, addressing the limitations of traditional single-layer nanobubbles by improving stability, control over drug release, drug loading capacity, and tissue penetration. Technical Problem

[0017] The primary technical problem addressed by the present invention is the need for an improved drug delivery system that can efficiently and effectively deliver multiple therapeutic agents to specific tissue sites, overcoming the limitations of traditional single-layer nanobubbles. These limitations include inadequate stability, insufficient control over drug release, limited drug loading capacity, and suboptimal tissue penetration. Traditional nanobubbles often struggle with incorporating and delivering both hydrophobic and hydrophilic drugs simultaneously, and existing methods typically only allow for surface loading, restricting the variety and quantity of drugs that can be delivered.

[0018] Furthermore, the short half-life of traditional nanobubbles and the challenges associated with maintaining drug stability and preventing premature degradation or metabolism in the bloodstream exacerbate these limitations. There is also a need to enhance the precision of drug delivery to target tissues while minimizing the impact on surrounding healthy tissues. Solution to Problem

[0019] The present invention provides an innovative solution to the technical problems associated with traditional single-layer nanobubbles through the development of bi- layer nanobubbles for drug delivery. This advanced system enhances the delivery of multiple therapeutic agents with improved efficiency and precision. The bi-layer structure of the nanobubbles addresses the limitations of conventional nanobubbles by offering enhanced stability, controlled drug release, increased drug loading capacity, improved tissue penetration, and versatile drug incorporation. These features collectively overcome the challenges of premature degradation, suboptimal drug release, and limited drug loading capacity, thereby significantly improving the efficacy of targeted drug delivery systems. Advantageous Effects of Invention

[0020] The invention presents several advantageous effects over traditional single- layer nanobubbles. The bi-layer configuration significantly improves the structural integrity and stability of the nanobubbles, extending their half-life in the bloodstream and ensuring they can effectively reach target tissues without premature degradation. This stability is crucial for maintaining the efficacy of the therapeutic agents.

[0021] Moreover, the bi-layer design allows for precise control over the release of encapsulated drugs. By incorporating different drugs into each layer, the release profiles can be finely tuned, ensuring therapeutic agents are released in a controlled manner at the target site. This minimizes systemic side effects and maximizes therapeutic efficacy.

[0022] The increased drug loading capacity of the bi-layer structure provides additional surface area and volume for drug incorporation. Hydrophobic drugs can be integrated into the inner layer, while hydrophilic drugs can be loaded into the outer layer. An additional third drug can be incorporated post-synthesis, significantly increasing the overall drug loading capacity.

[0023] Furthermore, the small size and bi-layer structure facilitate deeper penetration into tissues and cells. The invention leverages the ability of nanobubbles to scatter focused ultrasound waves, enhancing the precision of drug delivery and ensuring the therapeutic agents are effectively delivered to the intended tissue site.

[0024] The system also supports the incorporation of a wide variety of drugs, including hydrophobic, hydrophilic, and Exosome-derived drug. This versatility enables the delivery of complex multi-drug regimens, catering to diverse therapeutic needs.

[0025] Overall, these advantageous effects make the bi-layer nanobubble system a comprehensive and superior solution for efficient, controlled, and targeted drug delivery, with significant potential to improve the treatment of various diseases and conditions through enhanced drug delivery mechanisms. Brief Description of Drawings

[0026] New features of the present invention are set forth with characteristic features in the attached claims. A better understanding of the features and advantages of the present invention will be available through reference to the following detailed description, which sets forth representative embodiments in which the principles of the present invention are utilized, and to the accompanying drawings

[0027] FIG.1A illustrates a flowchart of a method for producing bilayer nanobubbles incorporating first and second drugs, consistent with one or more exemplary embodiments of the present disclosure.

[0028] FIG.1B illustrates a flowchart of a method for producing bilayer nanobubbles incorporating a first and a second drug during the synthesis process, with subsequent modification of the surface to incorporate a third drug, Exosome-derived drug, consistent with one or more exemplary embodiments of the present disclosure.

[0029] FIG. 2A illustrates an exploded view of a bilayer nanobubble incorporating drugs, consistent with one or more exemplary embodiments of the present disclosure.

[0030] FIG. 2B illustrates an exploded view of a hybrid of the extracted Exosome- derived drug (Ex) and nanobubbles (NB), consistent with one or more exemplary embodiments of the present disclosure.

[0031] FIG. 3A illustrates a Transmission Electron Microscopy (TEM) image of a bilayer nanobubble incorporating a drug, with a scale bar of 100 nm, consistent with one or more exemplary embodiments of the present disclosure.

[0032] FIG. 3B illustrates a Transmission Electron Microscopy (TEM) image of a bilayer nanobubble incorporating a drug, with a scale bar of 40 nm, consistent with one or more exemplary embodiments of the present disclosure.

[0033] FIG. 3C illustrates a Transmission Electron Microscopy (TEM) image of a bilayer nanobubble incorporating a drug, with a scale bar of 60 nm, consistent with one or more exemplary embodiments of the present disclosure.

[0034] FIG. 4A illustrates a dynamic light scattering (DLS) analysis of bilayer nanobubbles incorporating the first and the second drugs, consistent with one or more exemplary embodiments of the present disclosure.

[0035] FIG.4B illustrates a dynamic light scattering (DLS) analysis of hybrid bilayer nanobubbles incorporating the first and the second drugs and Exosome-derived drug, consistent with one or more exemplary embodiments of the present disclosure.

[0036] FIG. 5A illustrates a Fourier-Transform Infrared (FTIR) spectrum of a phospholipid bilayer (BL) membrane and a nanobubble (NB), consistent with one or more exemplary embodiments of the present disclosure.

[0037] FIG. 5B illustrates common peaks of the FTIR spectrum of a phospholipid bilayer membrane and a nanobubble incorporating curcumin, consistent with one or more exemplary embodiments of the present disclosure.

[0038] FIG. 5C illustrates specific peaks of the FTIR spectrum of a nanobubble incorporating curcumin, consistent with one or more exemplary embodiments of the present disclosure.

[0039] FIG.6 illustrates the measurement of the amount of drug entering a cell using High-Performance Liquid Chromatography (HPLC), consistent with one or more exemplary embodiments of the present disclosure.

[0040] FIG. 7 illustrates an intravenous injection of a specified drug compound, consistent with one or more exemplary embodiments of the present disclosure. Description of Embodiments

[0041] In the following detailed description, numerous specific details are set forth to provide a thorough understanding of the relevant teachings. However, it should be apparent that the present teachings may be practiced without such specific details. In other instances, well-known methods, procedures, components, and circuitry have been described in a manner that will be readily understood by those skilled in the art, in order to avoid unnecessarily obscuring aspects of the present teachings.

[0042] This detailed description is intended to enable a person skilled in the art to make and use the methods and devices disclosed in exemplary embodiments of the present invention. For explanatory purposes, specific nomenclature is used to provide a thorough understanding of the invention. However, it will be apparent to those skilled in the art that these specific details are not required to practice the disclosed exemplary embodiments. Descriptions of specific exemplary embodiments are provided as representative examples. Various modifications to the exemplary embodiments will be readily apparent to those skilled in the art, and the general principles defined herein may be applied to other embodiments and applications without departing from the scope of the present invention. The present invention is not intended to be limited to the embodiments shown but is to be accorded the widest scope consistent with the principles and features disclosed herein.

[0043] In describing and claiming the present invention, the following terminology will be used in accordance with the definitions set forth below. Unless otherwisedefined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. In the event of a conflict, the present document, including definitions, will control. As used herein, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. The terms "preferred" and "preferably" refer to embodiments of the invention that may afford certain benefits under certain circumstances. However, other embodiments may also be preferred under the same or other circumstances. Furthermore, the recitation of one or more preferred embodiments does not imply that other embodiments are not useful and is not intended to exclude other embodiments from the scope of the invention.

[0044] As used herein, the terms "comprising," "including," "having," "containing," "involving," "incorporating," and similar terms are to be understood as open-ended, meaning they include but are not limited to the listed elements. Thus, before describing the present invention in detail, it is understood that the invention is not limited to the specific embodiments or process parameters exemplified, which may, of course, vary. It is also understood that the terminology used herein is for the purpose of describing particular embodiments of the invention only and is not intended to limit the scope of the invention in any way. The use of examples anywhere in this specification, including examples of any terms discussed herein, is illustrative only and in no way limits the scope and meaning of the invention or of any exemplified term. Likewise, the invention is not limited to various embodiments given in this specification.

[0045] As used herein, the terms "hybrid" and "integration" are to be understood as open-ended, meaning they include but are not limited to the listed elements. As used herein, the term "nanobubble" refers to a bubble less than one micron in diameter that is hollow and contains a gas. As used herein, the term "phospholipid" refers to a lipid with one or more phosphate groups attached. As used herein, the term "drug" may be used interchangeably with the terms "therapeutic agent," "pharmaceutically active agent," or "bioactive agent," which, upon administration to a subject in a therapeutically effective amount, provides a therapeutic benefit to the subject in need thereof. The present invention contemplates a broad range of drugs or therapeutic agents and their use in conjunction with the nanobubble formulation, as further described herein. Non-limiting examples of suitabletherapeutic agents or drugs include carbohydrates, hydrophilic drugs, hydrophobic drugs, proteins, small molecules, antibodies, and peptides.

[0046] As used herein, the terms "drug loaded," "entrapped," "encapsulating," "incorporated," and "encapsulated" may be used interchangeably and refer to the incorporation, absorption, or adsorption of a drug or therapeutic agent by any means, in either the first or second layer of the nanobubbles. As used herein, the terms "delivery" and "delivering" refer to the conveyance of a therapeutic agent or drug to a subject using the methods of the invention. Delivery may be localized to a particular location in a subject, such as a tissue, an organ, or specific cells.

[0047] The present disclosure provides a method for producing bilayer nanobubbles incorporating drugs. An exemplary method may comprise preparing a thin lipid film that incorporates a first drug, hydrating the thin lipid film with PBS to form a suspension that incorporates a second drug, reducing the particle size of the suspension using an extruder, exposing the suspension to a neutral gas, and applying sonication at a lipid phase transition temperature to prepare the bilayer nanobubbles incorporating drugs.

[0048] FIG.1A presents an overview of the method for producing bilayer nanobubbles incorporating drugs, serving as a guide for the subsequent detailed description. The exemplary method outlined in FIG.1A entails several key steps: preparation of a thin lipid film 110, hydration of the film with PBS to form a suspension120, reduction of particle size through extrusion130, and the final creation of bilayer nanobubbles through exposure to a neutral gas and sonication at the lipid phase transition temperature 140. In one embodiment., a first drug, which in one exemplary embodiment may be a hydrophobic drug, can be incorporated 111. A second drug, which may be hydrophilic in one exemplary embodiment, can be incorporated 121 after hydrating of the thin film step 120.

[0049] The comprehensive method outlined in FIG.1A serves as a foundational the comprehensive method outlined in FIG. 1A serves as a foundational guide for fabricating bilayer nanobubbles incorporating drugs according to one and more embodiments of the present disclosure. It provides an overview of the key steps involved in the process, from the initial preparation of a thin lipid film to the final creation of bilayer nanobubbles incorporating drugs. However, to gain a deeperunderstanding of each step and its intricacies, further elaboration is required. In the subsequent sections, we will delve into the details of each step, elucidating the process to ensure clarity and comprehension.

[0050] The method for producing bilayer nanobubbles incorporating drugs as illustrated in FIG.1A begins with the step 110, in which phospholipids are dissolved in an organic solvent. The phospholipids utilized in step 110 for preparing the thin lipid film may encompass various phospholipids from a group, including but not limited to phosphatidylcholine (PC), phosphatidylglycerol (PG), phosphatidylserine (PS), phosphatidylethanolamine (PE), Distearoylphosphatidylcholine (DSPC), and dipalmitoyl phosphatidylcholine (DPPC). In one specific embodiment according to the present disclosure, DPPC and PE are used as the phospholipid.

[0051] In one embodiment, the organic solvent used for preparing the thin lipid film (step 110) may include ethanol, toluene, benzene, N-methyl-2-pyrrolidone (NMP), dimethyl sulfoxide (DMSO), acetone, chloroform, dimethylformamide, cyclohexane, tetrahydrofuran, and methylene chloride, consistent with one or more exemplary embodiments of the present disclosure. In a specific embodiment, the organic solvent may be chloroform.

[0052] In one exemplary embodiment according to present disclosure, phospholipids may be dissolved in chloroform at a concentration of around 12 mM and placed in a rotary device to allow the solvent to evaporate and form a thin film layer. Subsequently, to dehydrate the thin layer, the sample is exposed to the lipid phase transition temperature while gradually introducing PBS buffer with a pH of 7.4.

[0053] Continuing to Step 120, the prepared phospholipids are hydrated with PBS at the lipid phase transition temperature, forming a suspension. Within this suspension, in step 121, the incorporation of the second drug may occur. In one exemplary embodiment, a hydrophilic drug can be used as the second drug.

[0054] The first and the second drugs employed in the process (in step 111 and step 121) may encompass a diverse range, including hydrophobic fluorescent agents or dextran, curcumin, baicalein, oleuropein, resveratrol, calcein, and various phenolic compounds, alkaloids, and drug compounds with molecular weights below 500 Daltons. In one exemplary embodiment, Dextran may serve as a potential drug candidate to be incorporated. For Hydrophobic fluorescent agentsor dextran which can be used in one embodiment according to the present disclosure, dissolution in an organic solvent followed by addition to the phospholipid solution can be preferred, whereas the hydrophilic drugs can be typically added during the hydration step with PBS.

[0055] In one embodiment, the method may involve the incorporation of Cholesterol and PEG during the dissolution of phospholipids in chloroform 110, contributing to the formation of nanobubbles with adjustable drug dosages. During the dissolution of phospholipids in chloroform, cholesterol and PEG may be used at molar ratios of around 15% and 10% of DPPC and PE, respectively. The drug is then loaded into either the hydrophilic or hydrophobic regions within the nanobubble. The amount of drug incorporated into the nanobubble, for instance, dextran in one exemplary embodiment, can be adjusted to determine the optimal dosage for effective delivery.

[0056] Further advancing to Step 130, the suspension undergoes particle size reduction to nano size, via an extruder in one exemplary embodiment. In one exemplary embodiment, their particle diameter is reduced to 100 nm using a mini extruder and a 100 nm filter

[0057] Subsequently, in Step 140, the suspension is subjected to exposure to a neutral gas while sonication is applied at the lipid phase transition temperature, culminating in the creation of bilayer nanobubbles incorporating both the first and second drugs.

[0058] The lipid phase transition temperature according to one or more embodiment of the present disclosure, may typically falls within the range of 50-60°C.

[0059] Regarding the neutral gas utilized for producing the bilayer nanobubbles (step 140), a selection from sulfur fluorides such as sulfur hexafluoride (SF6) and perfluorocarbons such as CF4, C2F4, C2F6, and others can be considered. In particular embodiment according to the present disclosure, SF6 may use as neutral gas.

[0060] The stable gas incorporation phase may be conducted by sealing the suspension within a closed system. Initially, in one exemplary embodiment according to present disclosure, the suspension is pressurized with gas at 1 to 2 atmospheres, which can be repeated to ensure the desired gas content within thenanobubbles. Subsequently, the nanobubbles are recovered by gently inducing ultrasound waves at an intensity of 20 kHz and at the lipid phase transition temperature, which reduces the nanobubble size to below 60 nm.

[0061] FIG. 1B builds upon the steps outlined in FIG. 1A for producing bilayer nanobubbles incorporating a third drug. In addition to the previous steps (steps110 to140 as illustrated in FIG.1A), FIG.1B illustrates the additional steps (150 and 160) required to incorporate a third drug, onto the surface of the previously synthesized bilayer nanobubbles that already may contain the first and the second drugs.

[0062] In one exemplary embodiment according to FIG.1B, the process of producing bilayer nanobubbles, which have the first and second drugs incorporated in their respective layers, may further involve modifying the surface of these previously synthesized bilayer nanobubbles (step 150) to incorporate a third drug on their surface.

[0063] In one exemplary embodiment for modifying the surface of the bilayer nanobubbles, the following steps may be included. The details of each step are provided in the example sections of this application. Firstly, a first mixture is prepared and combined with the synthesized bilayer nanobubbles, resulting in a second mixture. This second mixture is then incubated and subsequently centrifuged to form a precipitate. The precipitate is dissolved in a solvent to create a uniform solution, which is sonicated to ensure the effective modification of the nanobubble surface, thereby preparing it for the incorporation of the third drug. In one embodiment, the third drug can be an Exosome-derived drug.

[0064] In one exemplary embodiment to incorporate the third drug, in one embodiment an Exosome-derived drug (step 160), is incorporated into the second mixture, maintaining a weight-to-weight ratio of Exosome-derived drug to nanobubbles of specific ratio. This mixture may be subjected to freeze-thaw cycles, consisting of freezing with liquid nitrogen and thawing in boiling water. This process may stabilize the incorporation of the Exosome-derived drug, as a third drug onto the nanobubbles, thereby producing nanobubbles incorporating the first, second, and third drugs.

[0065] FIG.2A presents an exploded view of a bilayer nanobubble engineered to accommodate both the first and second drugs consist with one or more exemplary embodiment of the present disclosure. These nanobubbles may feature a bilayer lipid membrane composed of cationic (positively charged phospholipid 201) and anionic (negatively charged phospholipid 202) constituents. Within this structure, hydrophilic compounds 203 and hydrophobic compounds 204 may distributed within the aqueous core 211 and between the lipid membrane layers, respectively. Moreover, the nanobubble's gas core 210 effectively traps gas. Additionally, molecules such as polyethylene glycol 212 and ligands like carbohydrates 205, proteins 206, small molecules 207, antibodies 208, and peptides 209 can be attached to the nanobubble surface to fulfill various functionalities and applications, aligning with one or more exemplary embodiments of the present disclosure.

[0066] In another embodiment, FIG.2B illustrates a schematic diagram showcasing the integration of extracted Exosome-derived drug s (Ex) as the third incorporated drug and Nanobubbles (NB), along with the mixing of their contents. This integration process involves subjecting the contents to ten cycles of freezing and thawing, alternating between liquid nitrogen and room temperature.

[0067] FIG.3 presents Transmission Electron Microscopy (TEM) images of synthesized bilayer nanobubbles incorporating drugs, showcasing sizes ranging from 40 nm (302), 60 nm (303), to 100 nm (301), in accordance with one or more exemplary embodiments of the present disclosure.

[0068] In FIG.4A, a size distribution graph of bilayer nanobubbles incorporating drugs is depicted, based on Dynamic Light Scattering (DLS) analysis. The average size of these nanobubbles, containing the first and second drugs, falls within the range of 30-100 nanometers, aligning with one or more exemplary embodiments of the present disclosure. Specifically, in one embodiment, the average size of the bilayer nanobubbles incorporating drugs measures approximately 90 nanometers, consistent with one or more exemplary embodiments of the present disclosure.

[0069] Furthermore, FIG.4B illustrates the size distribution graphs of bilayer nanobubbles incorporating the first, second, and third drugs, respectively, based on Dynamic Light Scattering (DLS) analysis. The DLS analysis was conducted three times to ensure accurate determination of the average particle size.

[0070] FIG.5A presents the Fourier Transform Infrared (FTIR) spectrum of the bilayer phospholipid membrane (BL) and the bilayer nanobubble incorporating drugs (NB). The identified peaks confirm the presence of gas and the model drug (curcumin) in the synthesized nanobubbles, aligning with one or more exemplary embodiments of the present disclosure.

[0071] FIG.5B displays a table enumerating common peaks in FTIR spectroscopy of the phospholipid bilayer membrane and the nanobubble incorporating curcumin, in accordance with one or more exemplary embodiments of the present disclosure.

[0072] FIG.5C illustrates a table delineating specific peaks in FTIR spectroscopy of the nanobubble incorporating curcumin.

[0073] FIG.6 depicts the quantification of drug entry into a cell using High-Performance Liquid Chromatography (HPLC) analysis. The analysis compares the amount of drug entering the cell alone (Cur), encapsulated in a nanobubble (NB-Cur), and under the influence of Focused Ultrasound waves (NB-Cur+FUS), indicating a significant increase in drug permeability to the target cell with the use of nanobubbles and focused ultrasound waves.

[0074] FIG.7 illustrates the intravenous injection of a specified pharmaceutical compound. The images depict a prone position before treatment (701), the prone position one hour after treatment (702), an image of a supine position before treatment (703), and the supine position one hour after treatment (704), consistent with one or more exemplary embodiments of the present disclosure.

[0075] In one exemplary embodiment, in the prone position where the individual is lying face down, the distribution and targeting of the drugs appear to be directed towards the brain. Furthermore, in the supine position where the individual is lying face up, it is noted that the drug does not disperse widely throughout other areas of the body. This observation suggests that the drug may be confined or better contained within the intended target area, such as the brain, without widespread dispersion to unintended regions. EXAMPLES EXAMPLE 1: First Mixture Preparation:

[0076] Combining 28 mM of EDC, 55 mM of NHS, and 23 mM of Apo-Transferrin in PBS buffer (pH 4.0) and incubating the mixture at 4°C for 2 hours with a rotational speed of 100 rpm. EXAMPLE 2: Second Mixture Preparation:

[0077] Adding the bilayer nanobubbles containing the first and second drugs (12 mM / mL) to the first mixture; incubating the combined mixture at 37°C for 24 hours with a rotational speed of 100 rpm; centrifuging the mixture at 1500 rpm for 24 hours to form a precipitate; and dissolving the precipitate in PBS buffer (pH 7.2) to obtain a uniform solution. EXAMPLE 2: Surface Modification:

[0078] Sonicating the homogeneous solution at 20 kHz for 10 minutes in a bath sonicator.

[0079] EXAMPLE 3: Exosome-derived drug Incorporation:

[0080] Mixing 100 microliters of the nanobubble solution (880 µg phospholipids) with 120 microliters of the Exosome-derived drug solution (63 µg Exosome-derived drug) at a 14:1 weight-to-weight ratio, and subject the mixture to 15 freeze-thaw cycles, with freezing in liquid nitrogen and thawing in boiling water for 25 minutes.

Claims

AMENDED CLAIMS received by the International Bureau on 13 November 2024 (13.11.2024)

1. This is a sample Claim. First Claim.

2. [Amended] This is a sample Claim. The claim or claims must "define the matter for which protection is sought." Claims must be clear and concise. They must be fully supported by the description. Rule 6 contains detailed requirements as to the number and numbering of claims, the extent to which any claim may refer to other parts of the international application, the manner of claiming, and dependent claims. As to the manner of claiming, the claims must, whenever appropriate, be in two distinct parts; namely, the statement of the prior art and the statement of the features for which protection is sought ("the characterizing portion").

3. [Cancelled]

4. This is a sample Claim. An international application should be drafted so that the claims relate to only one invention or to a group of inventions so linked as to form a single general inventive concept. This principle is laid down in Rule 13. Observance of this requirement is checked by neither the receiving Office nor the International Bureau, but it is checked by, and is important to the procedure before, the International Searching Authority (see paragraphs 281 to 287) and the International Preliminary Examining Authority (see paragraph 398), and may be relevant in the national phase before the designated and elected Offices.

5. This is a sample Claim. Since separate searches and examinations are required for distinctly different inventions, additional fees are required if the international search or international preliminary examination is to cover two or more inventions (or groups of inventions linked as just described).

6. [Added] This is a sample Claim. The physical requirements are the same as those for the description as outlined in paragraph 120. Note that the claims must commence on a new sheet.

7. [Added] This is a sample Claim. The claims may include tables if this is desirable in view of the subject matter involved. In this case, the tables must be included in the text of the relevant claim; they may not be annexed to the claims nor may reference be made to tables contained in the description (see paragraph 124).

8. The claims may be amended under Article 19 on receipt of the international search report (see paragraphs 296 to 303); they may also be amended during international preliminary examination if the applicant has filed a demand (see paragraphs 345 and 393) and during the national phase (see Volume II). i

Citation Information

Patent Citations

  • IN2919MU2013A